Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: MEDI8897; Drug: Placebo
Sponsor: MedImmune LLC
Not yet recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants
June 8, 2019ClinicalTrials.govComments OffInfections and Infectious DiseasesAttended | Efficacy | Evaluate | Healthy | Infants | Late | LRTI | MEDI8897 | Medically | Preterm | Prevention | Safety | Study | Term
Comments
